Latest Breaking News On - Titan partners group - Page 8 : comparemela.com

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMike moyerImmix biopharma incAmerican capital partnersExchange commissionTitan partners groupWorld trade centerPartners groupTrade centerImmix biopharmaSecurities litigation reform act

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkMike moyerTitan partners groupImmix biopharma incAmerican capital partnersExchange commissionWorld trade centerPartners groupTrade centerImmix biopharmaSecurities litigation reform act

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMike moyerTitan partners groupImmix biopharma incAmerican capital partnersWorld trade centerExchange commissionBiopharma announces closingPublic offeringPartners groupTrade centerImmix biopharmaSecurities litigation reform act

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 08, 2024 Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, announced today the closing of.

United statesNew yorkMike moyerTitan partners groupExchange commissionCompany contactImmix biopharma incAmerican capital partnersWorld trade centerPartners groupTrade centerImmix biopharmaSecurities litigation reform act

Immix Biopharma Announces Pricing of $15 Million Public

LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage.

United statesNew yorkMike moyerWorld trade centerAmerican capital partnersTitan partners groupExchange commissionImmix biopharma incPartners groupTrade centerImmix biopharmaSecurities litigation reform actNasdaq immxImmix biopharma